Loading...
Market
Will Massive Bio and Foundation Medicine partnership result in a new FDA-approved treatment by end of 2026?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA approval announcements, official press releases from Massive Bio or Foundation Medicine
Story
Massive Bio Partners with Foundation Medicine to Improve Cancer Clinical Trials at ESMO24
Sep 13, 2024, 12:09 PM
Biotech company Massive Bio has announced a partnership with Foundation Medicine to enhance clinical trial recruitment and enrollment, focusing on precision cancer care. The collaboration aims to address the low enrollment rates in cancer clinical trials by leveraging AI and genomic profiling. This partnership, highlighted at the ESMO24 conference, is seen as a pivotal step in developing solutions to the cancer clinical trial enrollment paradox, potentially allowing more patients to access advanced treatments.
View original story
Similar markets
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
